Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford.
Lung Cancer Video Library - Das - The Role of Immunotherapy for Unresectable Stage 3 NSCLC Today
dbrock
Image
For this addition to the Lung Cancer Video Library, Dr. Millie Das joins GRACE to discuss current updates in treatment options for non small cell lung cancer.
In this video, Dr. Das discusses updated information on the current role of immunotherapy for unresectable stage 3 non small cell lung cancer.
To join the conversation, visit https://cancergrace.org/forum.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Online Community
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...